These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16969334)

  • 21. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of thyroid malignancy in a hot nodule by fluorine-18-fluorodeoxyglucose positron emission tomography.
    Low SC; Sinha AK; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):304-7. PubMed ID: 15902360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
    Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?
    Slavikova K; Montravers F; Treglia G; Kunikowska J; Kaliska L; Vereb M; Talbot JN; Balogova S
    Curr Radiopharm; 2013 Jun; 6(2):96-105. PubMed ID: 23745775
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ruhlmann M; Ruhlmann J; Görges R; Herrmann K; Antoch G; Keller HW; Ruhlmann V
    Thyroid; 2017 Oct; 27(10):1300-1306. PubMed ID: 28793848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules.
    Sebastianes FM; Cerci JJ; Zanoni PH; Soares J; Chibana LK; Tomimori EK; de Camargo RY; Izaki M; Giorgi MC; Eluf-Neto J; Meneghetti JC; Pereira MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4485-8. PubMed ID: 17684046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
    Khan N; Oriuchi N; Higuchi T; Endo K
    Cancer Control; 2005 Oct; 12(4):254-60. PubMed ID: 16258498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid.
    Smith RB; Robinson RA; Hoffman HT; Graham MM
    Otolaryngol Head Neck Surg; 2008 Jan; 138(1):101-6. PubMed ID: 18165002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of F-18FDG PET in thyroid cancer.
    Lind P; Kumnig G; Matschnig S; Heinisch M; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Unterweger O
    Acta Med Austriaca; 2000; 27(2):38-41. PubMed ID: 10812462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
    Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.
    Basu S; Parghane RV
    PET Clin; 2017 Jan; 12(1):27-37. PubMed ID: 27863564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
    Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
    Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.